Experience

Davis Polk advised Oryzon Genomics, S.A. on its private placement of approximately 7,273,000 of its ordinary shares pursuant to a capital increase. The offering consisted of two tranches: a…

Davis Polk advised the representatives of the several underwriters in connection with the $296 million SEC-registered offering of 9,545,000 shares of common stock of 1Life Healthcare,…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $69 million follow-on offering of common stock of Magenta Therapeutics…

Davis Polk advised the sole book-running manager in connection with the $215.6 million common stock offering of 6,900,000 shares of common stock of Editas Medicine, Inc. The common…

Davis Polk advised the joint book-running managers on an SEC-registered offering by Abbott Laboratories of $650 million aggregate principal amount of 1.150% notes due 2028 and $650…

Davis Polk advised the representative of the initial purchasers of a Rule 144A/Regulation S offering by Acadia Healthcare Company, Inc. of $450 million aggregate principal amount of its 5…

Davis Polk advised the representatives of the underwriters, in connection with the offering of $4.5 billion aggregate principal amount of notes issued by Merck & Co., Inc. The…

Davis Polk advised the initial purchaser in connection with a Rule 144A offering by CryoLife, Inc. of $100 million aggregate principal amount of its 4.250% convertible senior notes due 2025…

Davis Polk advised Genetron Holdings Limited on its SEC-registered initial public offering of 16,000,000 American Depositary Shares. Each ADS represents five ordinary shares. Genetron has…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $124.7 million SEC-registered offering of 28,503,220 shares of…